State NAMI chapters get millions from pharma; WHO decides on recall for Shantha vaccine;

   @FiercePharma: GSK 'absorbs' reform costs in strong Q1. Story | Follow @FiercePharma

> State chapters of the National Alliance on Mental Illness received several million dollars in contributions from pharma companies in a little less than five years, with big donations from Eli Lilly, AstraZeneca and Bristol-Myers Squibb, according to a letter from Sen. Charles Grassley. Report

> The WHO has called for recall and destruction of all batches of Indian drugmaker Shantha Biotechnics' Shan5 vaccine after the discovery of "white sediment" in some vials. Report

> Shire posted better-than-expected first-quarter earnings on Thursday as new drugs offset loss of exclusivity for its blockbuster ADHD medicine Adderall XR. Release | Report

> Mylan posted a better-than-expected first-quarter profit, helped by strong overseas sales, and the generic drugmaker maintained its full-year forecast. Release | Report 

> Medicines Co. posted a better-than-expected quarterly profit of $9.4 million, or 18 cents per share, helped by lower operating expense. Release | Report

> Russian drugmaker Pharmstandard says its net profit nearly doubled last year on higher sales of medicines, especially its popular Arbidol flu drug. Release | Report

> Labopharm says it was forming a joint venture with Italy's Grupo Angelini to sell the Canadian drugmaker's trazodone antidepressant in the U.S. Release | Report

> Pharmaceutical giant Pfizer has lost the sole right to manufacture Viagra in Brazil after judges decided the market for the drug should be opened up. Report

Biotech News

 @FierceBiotech:   E&Y: A resilient biotech industry registers its first profitable year. Article | Follow @FierceBiotech 

 @JohnCFierce:  Pfizer developing "bio-betters," seeking rare blood disorder drugs. Article | Follow @JohnCFierce

> Novartis CEO plans to keep China R&D ops in-house. Report

> Affimed raises €20M to fund innovative antibody trials. Item

> Bill Gates bets $10M on the future of drug development software. Story

> R&D success puts Alexion at the top of the M&A list. Article

> PhDs face a tough job market as biotechs get lean and mean. Item

Vaccines News

> Novavax reports mild response in PhII seasonal flu trial. Article

> Biotechs explore promise of oncolytic immunity. Report

> CSL shares plunge on flu vax safety concerns. Story

> AFFiRiS readies Alzheimer's vax for PhII study. Item

> H1N1 vax monitoring flags potential risks. News

Manufacturing News

> FDA warns Teva (again) on propofol plant. Article

> Parenteral packaging rises to patient-compliance, brand challenges. Story

> EU okays prescription drug anticounterfeiting measures. Item

> Sebelius keeps vaccine manufacturing tech in spotlight. News

And Finally... The FDA is urging drugmakers to strengthen security practices to help prevent cargo theft. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.